Table 1. Clinical and hematological features of patients with essential thrombocythemia with respect to JAK2 and CALR mutation status.
| Variable | JAK2 V617F mutation (n = 78) | CALR mutation (n = 39) | P |
|---|---|---|---|
| Age median (yr, range) | 63.5 (21-85) | 52 (8-94) | < 0.05 |
| Sex (M/F) | 30/48 | 28/11 | < 0.01 |
| WBC ( × 109/L, median, range) | 10.6 (4.5-46.7) | 9.0 (3.4-22.4) | n.s. |
| Granulocytes ( × 109/L, mean ± SD) | 8.2 ± 5.5 | 6.9 ± 4.5 | n.s. |
| Hb ( g/L, mean ± SD) | 143 ± 21 | 136 ± 16 | < 0.05 |
| Plt ( × 109/L, mean ± SD) | 947 ± 525 | 1143 ± 599 | < 0.05 |
| Ferritin (μg/L, mean ± SD) | 85.0 ± 75.4 | 158.8 ± 87.2 | < 0.01 |
| Erythropoietin (IU/L, mean ± SD) | 11.8 ± 7.0 | 36.4 ± 9.9 | < 0.01 |
| Leukocyte alkaline phosphatase score (mean ± SD) | 270.6 ± 86.1 | 166.6 ± 52.9 | < 0.01 |
| Splenomegaly (presence/examined, %) | 23/52 (45%) | 11/24 (46%) | n.s. |
| Thrombosis during follow-up (presence/examined, %) | 21/77 (26%) | 3/39 (7.7%) | < 0.05 |
Distribution of variables was evaluated by using the Kolmogorov-Smirnov test, and all except for the number of WBC were distributed normally.
Abbreviations: WBC, white blood cell; Plt, platelet; n.s., no significance.